[go: up one dir, main page]

US20020013331A1 - Methods and compositions for treating pain of the mucous membrane - Google Patents

Methods and compositions for treating pain of the mucous membrane Download PDF

Info

Publication number
US20020013331A1
US20020013331A1 US09/888,466 US88846601A US2002013331A1 US 20020013331 A1 US20020013331 A1 US 20020013331A1 US 88846601 A US88846601 A US 88846601A US 2002013331 A1 US2002013331 A1 US 2002013331A1
Authority
US
United States
Prior art keywords
composition
percent
pharmaceutically
mucoadhesive
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/888,466
Other languages
English (en)
Inventor
Robert Williams
Feng Zhang
John Koleng
Gavril Pasternak
Yuri Kolesnikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/888,466 priority Critical patent/US20020013331A1/en
Publication of US20020013331A1 publication Critical patent/US20020013331A1/en
Priority to US10/172,455 priority patent/US6509028B2/en
Priority to US10/347,385 priority patent/US20030124190A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to methods and compositions for treating the pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma.
  • mucous membrane refers to the moist linings of the buccal cavity, nasal cavity, gastrointestinal tract, respiratory tract, conjunctiva, vagina, colon, urinary bladder, and urethra (Forstner et al., 1973 J. Cell. Sci. 12:585; Peppas et al., 1985 J Control Release 2:257; Lehr et al., 1992 J. Control. Release 18:249; Spiro, 1970 Ann. Rev. Biochem. 39:599; Lebat-Robert et al., 1979 Path. Biol. 24:241).
  • the normally smooth, moist, and pink buccal mucosa is very sensitive and inflamation or ulceration (oral mucositis) causes severe pain.
  • Dental surgery such as root canal and tooth extraction can also severely damage the buccal mucosa causing severe pain.
  • oral mucositis and dental surgery can induce secondary conditions, such as weight loss and dehydration from reluctance to eat or drink, infection (bacterial, fungal, and viral), fever, nausea, and diarrhea.
  • Oral mucositis has a variety of causes, for example, bacterial infections, such as streptococci; viral infections, such as herpes simplex virus; fungal infections; side effects of systemic diseases; vitamin deficiency; iron deficiency; cheek biting; mouth breathing; jagged teeth; orthodontic appliances; ill-fitting dentures; excessive use of alcohol or tobacco; thermally-hot foods; spicy foods; and as a side effect of medication.
  • Severely-painful oral mucositis is a symptom endured by almost all chemotherapy patients. Mucositis symptoms peak 7 to 10 days following chemotherapy, and gradually recede over the following two weeks.
  • Topical application of local anesthetics can provide some relief of oral-mucositis and dental-surgery pain but absorption through the mucous membranes occurs rapidly, and pharmaceuticals applied to the mucous membrane for their local effect sometimes cause systemic toxicity ( Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. J. G. Harman and L. E. Limird Eds., McGraw-Hill New York 1996 p. 8) especially with the higher doses required for adequate pain relief. Systemic absorption is even more likely when the mucous membrane is ulcerated or inflamed.
  • anesthetic compositions for mucositis e.g., 2 percent lidocaine oral rinse or 5% lidocaine ointment
  • systemic toxicity limits the dosage and so adequate pain relief is difficult to achieve.
  • Other less toxic pain relieving compositions such as rinses comprising hydrogen peroxide and sodium bicarbonate are less effective at reducing pain.
  • An additional problem with oral rinses is, that following application, the action of swallowing and saliva reduces the concentration of active agent on the affected area, thus oral rinses comprising local anesthetics have a low duration of activity.
  • the invention provides compositions and methods that provide long-lasting local anesthesia and effective pain relief.
  • the compositions of the invention can be topically applied to the affected area, for example, via a dose-metered applicator adapted for spraying or adapted for use with a cannula.
  • the compositions of the invention provide a powerful local-anesthetizing effect, in spite of low anesthetic concentration.
  • the compositions of the invention provide significant pain relief with low systemic absorption and, therefore, low systemic toxicity.
  • the compositions of the invention in addition to the ability to remain on the affected area for extended periods, hydrate and soothe.
  • compositions of the invention can be topically applied directly to the affected area to alleviate pain in a subject on any area of a subject's body.
  • compositions of the invention are useful for topical application to a subject's mucous membrane, to induce a long-lasting local-anesthetic effect, thereby relieving pain from mucositis, such as mucosal inflamation, abrasions, ulcerations, and lesions, without significant systemic absorption.
  • compositions of the invention are useful for topical application to the site of dental surgery, such as root-canal or tooth-extraction surgery, to induce a long-lasting local-anesthetic effect, thereby relieving the surgical pain, without significant systemic absorption.
  • the invention relates to compositions comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof.
  • the compositions contain water and are sterile.
  • the compositions of the invention further comprise a chelating agent and a preservative.
  • the invention in another embodiment, relates to a container adapted for topical application and containing a pharmaceutically-acceptable composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof.
  • the container is adapted for dose-metered application, such as a dose-metered pump for use with a spray applicator or cannula.
  • the invention relates to a method of inducing local anesthesia in a subject's mucosal membrane by topically applying a pharmaceutically-acceptable composition comprising a local anesthetic or a pharmaceutically-acceptable salt thereof and an opioid or a pharmaceutically-acceptable salt thereof to the subject's mucosal membrane.
  • a pharmaceutically-acceptable composition comprising a local anesthetic or a pharmaceutically-acceptable salt thereof and an opioid or a pharmaceutically-acceptable salt thereof to the subject's mucosal membrane.
  • the composition is applied to an area within the subject's buccal or nasal cavity.
  • the composition further comprises a mucoadhesive.
  • the invention relates to a method of inducing local anesthesia in a subject by topically applying a composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof to a subject.
  • a composition comprising a mucoadhesive, a local anesthetic or a pharmaceutically-acceptable salt thereof, and an opioid or a pharmaceutically-acceptable salt thereof to a subject.
  • the composition is applied to a mucosal surface of the subject, for example, an area within the subject's buccal or nasal cavity.
  • phrases “pharmaceutically-acceptable salt(s),” as used herein includes but is not limited to salts of acidic or basic groups that may be present in compounds used in the present compositions.
  • Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically-acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including, but not limited to, sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfon
  • Compounds included in the present compositions that include an amino moiety may form pharmaceutically-acceptable salts with various amino acids, in addition to the acids mentioned above.
  • Compounds, included in the present compositions, that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
  • opioid means all agonists and antagonists of opioid receptors, such as mu ( ⁇ ), kappa ( ⁇ ), and delta ( ⁇ ) opioid receptors and subtypes thereof.
  • opioid receptors and subtypes see Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. J. G. Harman and L. E. Limird Eds., McGraw-Hill New York:1996 pp. 521-555, incorporated herein by reference.
  • the opioid can be any opioid receptor agonist or antagonist known or to be developed.
  • Preferred opioids interact with the ⁇ -opioid receptor, the ⁇ -opioid receptor, or both.
  • the opioid is an opioid-receptor agonist.
  • Suitable opioids for use with the invention include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, benzitramide, nor-binaltorphimine, bremazocine, buprenorphine, butorphanol, clonitazene, codeine, CTOP, DAMGO, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydrocodeine enol acetate, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprenorphine, DPDPE, eptazocine, ethoheptazine, ethylketocyclazocine, ethyhnethylthiambutene, etonitazene, et
  • Examples of peptide opioids include, but are not limited to, Tyr-Gly-Gly-Phe-Leu ([Leu 5 ]enkephalin), Tyr-Gly-Gly-Phe-Met ([Met 5 ]enkephalin), Tyr-Gly-Gly-Phe-Leu-Arg -Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln (DynorphinA), Tyr-Gly-Gly-Phe-Leu -Arg-Arg-Gln-Phe-Lys-Val-Val-Thr (Dynorphin B), Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr -Pro-Lys ( ⁇ -Neoendorphin), Tyr-Gly-Gly-Phe-Leu-Arg-Lsy-Tyr-Pro ( ⁇ -Neoendorphin), Tyr-Gly-Gly-Phe-Leu
  • Preferred opioids include morphine, loperamide and loperamide derivatives such as those disclosed in U.S. Pat. Nos. 5,763,445; 5,981,513; 5,869,521; 5,744,458; 5,760,023; 5,798,093; 5,849,762; 5,811,078; 6,004,964; 5,962,477; 5,688,955; 5,888,494; 5,646,151; and 5,667,773 (all of which patents are incorporated by reference herein), or pharmaceutically-acceptable salts thereof, or mixtures thereof.
  • the most preferred opioid is morphine or a pharmaceutically-acceptable salt thereof.
  • local anesthetic means any drug that provides local numbness or analgesia or any drug that provides a regional blockage of nociceptive pathways (afferent and/or efferent) and that is not an agonist or an antagonist of an opioid receptors.
  • the local anesthetic can be any local anesthetic known or to be developed.
  • Examples of local anesthetics suitable for use with the invention include: ambucaine, amolanone, amylcaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dyclonine, ecogonidine, ecogonine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxyteteracaine, isobutyl ⁇ -aminobenzoate, leucinocaine, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine,
  • the amide and ester type local anesthetics are preferred.
  • Amide type local anesthetics are characterized by an amide functionality, while ester type local anesthetics contain an ester functionality.
  • Preferred amide type local anesthetics include lidocaine, bupivacaine, prilocaine, mepivacaine, etidocaine, ropivacaine, dibucaine, and pharmaceutically-acceptable salts thereof and mixtures thereof.
  • Preferred ester type local anesthetics include tetracaine, procaine, benzocaine, chloroprocaine, and pharmaceutically-acceptable salts thereof and mixtures thereof. The most preferred local anesthetic is lidocaine.
  • local anesthetic also encompasses drugs not traditionally associated with local anesthetic properties but which have a local-anesthetic effect, for example, non-narcotic analgesics, such as, acetylsalicylic acid, ketoprofen, piroxicam, diclofenac, indomethacin, ketorolac, Vioxx®, and Celebrex®.
  • non-narcotic analgesics such as, acetylsalicylic acid, ketoprofen, piroxicam, diclofenac, indomethacin, ketorolac, Vioxx®, and Celebrex®.
  • local anesthetics with different pharmacodynamics and pharmacokinetics may be combined in a composition of the invention.
  • a preferred combination of local anesthetics is lidocaine and prilocaine and another preferred combination is lidocaine and tetracaine.
  • the term “local delivery” of a therapeutic means topical application of the therapeutic to a subject, whereafter a therapeutically-effective amount of the therapeutic is absorbed in the immediate application area, preferably, without significant absorption into the blood stream.
  • a “therapeutically-effective amount” of the compositions of the invention means the amount required to induce a local-anesthetic effect or numbness sufficient to ameliorate pain induced by ulceration, inflamation, or lesions of the buccal or nasal membrane or other mucous membranes or the pain associated with mucosal trauma, such as dental surgery.
  • the active agents of the composition are not absorbed systemically.
  • the term “subject” means any animal, preferably a mammal, more preferably a human.
  • mucoadhesive means a natural or synthetic substance, e.g., gels, pastes, macromolecules, polymers, and oligomers, or mixtures thereof, that can adhere to a subject's mucous membrane for a period of time sufficient to locally deliver a therapeutically-effective amount of a composition of the invention to a subject. Adhesion of mucoadhesives to the mucous membrane occurs primarily via secondary chemical bonds, such as hydrogen bonding and Van der Waal forces (Tabor et al., 1977 J Colloid Interface Sci. 58:2 and Good 1977 J Colloid Interface Sci. 59:398). Mucoadhesive substances often form viscous aqueous solutions.
  • the composition itself does not need to be mucoadhesive, as long as it can form a mucoadhesive gel upon on the contact with the mucous membrane.
  • gellan gum itself is a very weak mucoadhesive.
  • gellan gum can interact with the ions in the mucous membrane and form an adhesive gel layer.
  • mucoadhesives possess binding properties that may be distinguished from non-mucoadhesives by comparing the degree of adhesion to a mucosal surface.
  • a potential mucoadhesive with a control emulsion of comparable viscosity prepared without mucoadhesive properties, e.g., a starch solution.
  • the emulsion prepared with the mucoadhesive will bind to the mucosal surface more strongly than will the control emulsion, preferably at least 25% greater mucosal binding than the control emulsion, more preferably at least 50% greater, still more preferably at least 100% greater mucosal binding.
  • Either mechanical binding to mucous membrane per se or the degree of biological effect of a drug delivered may be used as a measurement parameter for mucoadhesion. This test may be used to distinguish preferred mucoadhesives.
  • Substances can be screened for their ability to be used as mucoadhesives for local delivery of compositions of the invention according to the methodology described in Smart et aL, 1982 J Pharm. Pharmacol. 34:70P and Smart et al., 1984 J Pharm. Pharmacol. 36:295, which methodology comprises estimating values of adhesive strength between the substance and the mucous membrane.
  • the mucoadhesive is water soluble, such that at least 1% by weight of the mucoadhesive is soluble in water at 25° C.
  • the mucoadhesive will exhibit non-Newtonian fluid properties, i.e., the viscosity decreases with increasing shear forces.
  • the viscosity of the composition can be modulated by altering the shear forces present when the composition is applied to a surface.
  • a composition with non-Newtonian fluid properties becomes less viscous when shaken or atomized, then, upon standing, returns to its original viscosity.
  • mucoadhesives for use in the present invention include, but are not limited to, pectin, alginic acid, chitosan, hyaluronic acid, polysorbates, such as polysorbate-20, -21, -40, -60, -61, -65, -80, -81, -85; poly(ethyleneglycol), such as PEG-7, -14, -16, -18, -55, -90, -100, -135, -180, -4, -240, -6, -8, -9, -10, -12, -20, or -32; oligosaccharides and polysaccharides, such as gellan, carrageenan, xanthan gum, gum Arabic, and dextran; cellulose esters and cellulose ethers; modified cellulose polymers, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose;
  • poly(ethylene oxide) for example, condensation products of poly(ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols; polyether compounds, such as poly(methyl vinyl ether), polyoxypropylene of less than 10 repeating units; polyether compounds, such as block copolymers of ethylene oxide and propylene oxide; mixtures of block copolymers of ethylene oxide and propylene oxide with other excipients, for example, pluronic lethicin organogel (see 1997 International Journal of Pharmaceutical Compounding 1:71); poly(vinyl alcohol); polyacrylamide; hydrolyzed polyacrylamide; poly(vinyl pyrrolidone); poly(methacrylic acid); poly(acrylic acid) or cosslinked polyacrylic acid, such as carbomer, i.e., a homopolymer of acrylic acid crosslinked with either an allyl ether of pentaerythritol, an allyl ether of sucrose, or an
  • x is an integer having an average value within the range of from about 2 to about 128
  • y is an integer having an average value within the range of from about 14 to about 80
  • z is an integer having an average value within the range of from about 2 to about 128.
  • x and y are about equal.
  • More preferred block copolymers of ethylene oxide and propylene oxide, falling within the genus represented by formula I, are shown in Table 1 below.
  • the most preferred mucoadhesive for use with the invention is poloxamer 407.
  • the block copolymers of ethylene oxide and propylene oxide sold under the trade name Pluronic are commercially available, e.g., BASF (Washington, N.J.).
  • the block copolymers of ethylene oxide and propylene oxide sold under the trade name Calgene are commercially available, e.g., Calgene Chemical, Inc. Skokie, Ill.
  • compositions of the invention when administered to a subject, are sterile.
  • Suitable preservatives include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride; mercurial agents, such as phenylmercuric nitrate, phenylmercuric acetate, and thimerosal; alcoholic agents, for example, chlorobutanol, phenylethyl alcohol, and benzyl alcohol; antibacterial esters, for example, esters of para-hydroxybenzoic acid; and other anti-microbial agents such as chlorhexidine, chlorocresol, and polymyxin.
  • quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimide, dequalinium chloride, and cetylpyridinium chloride
  • mercurial agents such as phenylmercuric nitrate, phenylmercuric
  • Suitable chelating agents include, but are not limited to, deferoxamine, ditiocarb sodium, edetate calcium disodium, edetate disodium, edetate sodium, edetate trisodium, penicillamine, pentetate calcium trisodium, pentetic acid, succimer, trientin.
  • the pH of the composition is within the range of from about 2 to about 9, more preferably, about 3 to about 7, even more preferably about 4 to about 5, and optimally about 4.5.
  • the pH can be adjusted by adding an aqueous acid or base, dropwise to the composition until the desired pH is obtained.
  • any physiologically acceptable pH adjusting acids, bases or buffers are acceptable, e.g., acids, such as acetic, boric, citric, lactic, phosphoric, hydrochloric; bases, such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, THAM (trishydroxymethylaminomethane); and buffers such as citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures thereof, preferably, 0.1 normal hydrochloric acid for a pH of less than 7 and 0.1 normal aqueous sodium hydroxide for a pH of greater than 7.
  • acids such as acetic, boric, citric, lactic, phosphoric, hydrochloric
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, THAM (trishydroxymethylaminomethane)
  • buffers such as citrate/dextrose, sodium bicarbonate, ammonium chloride and mixture
  • composition of the invention can also comprise NMDA receptor antagonists including, but not limited to, dextromethorphan, dextrorphan, ketamine, pyroloquinolin quinone, cis-4-(phosphonomethyl)-2-piperidine carboxylic acid, MK801, memantine, D-methadone, or pharmaceutically-acceptable salts thereof.
  • NMDA receptor antagonists including, but not limited to, dextromethorphan, dextrorphan, ketamine, pyroloquinolin quinone, cis-4-(phosphonomethyl)-2-piperidine carboxylic acid, MK801, memantine, D-methadone, or pharmaceutically-acceptable salts thereof.
  • compositions of the invention can also include other excipients and pharmaceuticals.
  • excipients that can be included in the topical compositions of the invention include, but are not limited to, antibiotics, analgesics, antifingal agents, non-steroidal anti-inflammatory agents, anti-tussive agents, expectorants, glucocorticoids, vitamins, anti-oxidants, flavoring agents, sweetening agents, iso-osmotic agents, moisturizers, emollients, buffering agents, solubilizing agents, penetration agents, protectants, surfactants, and propellants, and other conventional systemic or topical pain relief therapies, analgesics, and pharmaceuticals.
  • antibiotics include, but are not limited to, aminoglycoside antibiotics; such as apramycin, arbekacin, bambermycins, butirosin, dibekacin, neomycin, neomycin undecylenate, netilmicin, paromomycin, ribostamycin, sisomicin, and spectinomycin; amphenicol antibiotics, such as azidamfenicol, chloramphenicol, florfenicol, and thiamphenicol; ansamycin antibiotics, such as rifamide and rifampin; carbacephems, such as loracarbef; carbapenems, such as biapenem and imipenem; cephalosporins, such as cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefazedone, cefozopran, cefpimizole, cefpiramide, and cef
  • analgesics include, but are not limited to, aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylsalicylic acid, alclofenac, alminoprofen, aloxiprin, aluminum bis(acetylsalicylate), aminochlorthenoxazin, 2-amino-4-picoline, aminopropylon, aminopyrine, ammonium salicylate, amtolmetin guacil, antipyrine, antipyrine salicylate, antrafenine, apazone, aspirin, benorylate, benoxaprofen, benzpiperylon, benzydamine, bermoprofen, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bucetin, bufexamac, bumadizon, butacetin, calcium acetylsalicylate,
  • Suitable antifungal agents include, but are not limited to, polyenes, such as amphotericin b, candicidin, mepartricin, natamycin, and nystatin; allylamines, such as butenafine, and naftifine; imidazoles, such as bifonazole, butoconazole, chlordantoin, flutrimazole, isoconazole, ketoconazole, and lanoconazole; thiocarbamates, such as tolciclate, tolindate, and tolnaftate; triazoles, such as fluconazole, itraconazole, saperconazole, and terconazole; and others, such as bromosalicylchloranilide, buclosamide, calcium propionate, chlorphenesin, and ciclopirox; and others, such as azaserine, griseofulvin, oligomycins, neomycin undecylenate,
  • non-steroidal anti-inflammatory agents include, but are not limited to, aminoarylcarboxylic acid derivatives, such as enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, and tolfenamic acid; arylacetic acid derivatives, such as aceclofenac, acemetacin, alclofenac, amfenac, amtolmetin guacil, bromfenac, bufexamac, cimnetacin, clopirac, diclofenac sodium, etodolac, felbinac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac isoxepac, lonazolac, metiazinic
  • antitussive agents include, but are not limited to, alloclamide, amicibone, benproperine, benzonatate, bibenzonium bromide, bromoform, butamirate, butethamate, caramiphen ethanedisulfonate, carbetapentane, chlophedianol, clobutinol, cloperastine, codeine, codeine methyl bromide, codeine ⁇ -oxide, codeine phosphate, codeine sulfate, cyclexanone, dimethoxanate, dropropizine, drotebanol, eprazinone, ethyl dibunate, ethylmorphine, fominoben, guaiapate, hydrocodone, isoaminile, levopropoxyphene, morclofone, narceine, mormethadone, noscapine, oxeladin, oxolamine,
  • Example of suitable expectorants include, but are not limited to, ambroxol, ammonium bicarabonate, ammonium carbonate, bromhexine, calcium iodide, carbocysteine, guaiacol, guaiacol benzoate, guaiacolcarbonate, guaiacol phosphate, guaifenesin, guaithylline, hydriodic acid, iodinated glycerol, potassium guaiacolsulfonate, potassium iodide, sodium citrate, sodium iodide, storax, terebene, terpin, and trifolium.
  • Suitable glucocorticoids include, but are not limited to, 21 -acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, flucortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, flupre
  • Suitable vitamins include, but are not limited to calcipotriene, calcitriol, ergosterol, 1 ⁇ -hydroxycholecalciferol, vitamin D 2+ , vitamin D 3+ , ascorbic acid, calcium ascorbate, nicotinamide ascorbate, sodium ascorbate, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, vitamin ⁇ , cobamamide, folic acid, hydroxocobalamin, sodium folate, vitamin B 12 , menadiol, menadione, menadoxime, menaquinones, phylloquinone, vitamin K 5+ , inositol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, vitamin E, vitamin E acetate, and vitamin U.
  • Suitable anti-oxidants include, but are not limited to, ascorbic acid, sodium ascorb ate, sodium bisulfite, sodium thio sulfate, 8-hydroxy quinoline, and N-acetyl cysterine.
  • suitable flavoring agents include, but are not limited to, oil of spearmint, peppermint, wintergreen, sassafras, clove, sage, eucalyptus, marjoram, cinnamon, lemon, and orange, and methyl salicylate.
  • suitable sweetening agents include, but not limited to, sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), and saccharine.
  • compositions of the present invention optionally can include an iso-osmotic agent which functions to prevent irritation of the mucosa by the composition.
  • iso-osmotic agents which can be used include sodium chloride, dextrose, and calcium chloride.
  • the amount of local anesthetic in the composition is within the range of from about 0.005 percent to about 2 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 0.5 percent of the total weight of the composition.
  • a preferred concentration of local anesthetic is from about 0.02 percent to about 0.1 percent of the total weight of the composition, more preferably, about 0.04 percent to about 0.08 percent.
  • a preferred concentration of local anesthetic is from about 0.1 percent to about 0.4 percent of the total weight of the composition, more preferably, about 0.2 percent to about 0.3 percent.
  • the amount of opioid in the composition is within the range of from about 0.005 percent to about 3 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 2 percent, still more preferably, of from about 0.05 percent to about 1 percent of the total weight of the composition.
  • a preferred concentration of opioid is from about 0.1 percent to about 0.3 percent of the total weight of the composition.
  • a preferred concentration of opioid is from about 0.3 percent to 20 about 0.8 percent of the total weight of the composition, more preferably, about 0.4 percent to about 0.5 percent.
  • the amount of mucoadhesive in the composition is within the range of from about 0.1 percent to about 40 percent of the total weight of the composition, more preferably, of from about 10 percent to about 30 percent, and optimally, of from about 15 percent to about 25 percent of the total weight of the composition.
  • the amount of water in the composition is within the range of from about 95 percent to about 10 percent of the total weight of the composition, more preferably, of from about 90 percent to about 50 percent, and optimally, of from about 85 percent to about 75 percent of the total weight of the composition.
  • a chelating agent when used, preferably, it is present in an amount within the range of from about 0.005 percent to about 1 percent of the total weight of the composition, more preferably, of from about 0.01 percent to about 0.5 percent, still more preferably, of from about 0.05 percent to about 0.2 percent of the composition.
  • a preservative when used, preferably, it is present in an amount within the range of from about 0.0001 percent to about 0.2 percent of the total weight of the composition, more preferably, of from about 0.0005 percent to about 0.1 percent, and optimally, of from about 0.001 percent to about 0.05 percent of the total weight of the composition.
  • compositions or the invention are topically applied directly to the affected area.
  • the compositions of the invention can be applied to the affected area of the mucous membrane in any conventional manner well known in the art, for example, as a mist via an aerosol applicator, by cannula, via a patch, by a dropper, or by an applicator stick, preferably as a mist, more preferably as a metered-dose mist.
  • a mist can be sprayed onto the area to be treated via an aerosol container, pressurized or non-pressurized, preferably a non-pressurized pump.
  • a cannula can be used.
  • the cannula can be attached to a pressurized or non-pressurized pump, preferably a non-pressurized pump.
  • a suitable non-pressurized pump for application of compositions of the invention can comprise a container, a valve, an actuator, and optionally a dip tube.
  • the non-pressurized pump's container can be metal, such as a tin plated steel or aluminum, glass, or plastic.
  • the valve's primary purpose is to regulate the flow of product from the container. It provides a means of discharging the desired amount.
  • Suitable spray valves are described in Remington's Pharmaceutical Sciences 18th Edition, ed. Alfonso Gennaro, Mack Publishing Co. Easton, Pa., 1990 pp. 1703-1704, incorporated herein by reference.
  • the actuator provides a means for releasing the contents from a pressurized container. Suitable actuators are described in Remington's Pharmaceutical Sciences 18th Edition, ed. Alfonso Gennaro, Mack Publishing Co. Easton, Pa., 1990 pp. 1704-1705, incorporated herein by reference.
  • the metered pump is a VP 7 Screw-On Pump (90 ⁇ l, 18/415) commercially available from Valois of America, Inc. (Greenwich, Conn.).
  • the VP 7 screw-on pump is manufactured from polyethylene and polypropylene. It is designed in a way such that the hydraulically opening clapper eliminates the use of any elastomeric gaskets in contact with the product.
  • the pump has an annular dosing chamber, which fills only at the full return of the actuator to ensure full dosing and precision.
  • the preferred actuator is the 132C-BL GP4 BL long throat actuator commercially available from Valois Pharmaceuticals, Inc.
  • the actuator is manufactured from polyethylene and polypropylene and, preferably, contains a captive insert to provide a well-atomized spray pattern. The captive insert also reduces the dead volume in the actuator.
  • the preferred actuator is a stainless-steel cannula of about 73 mm in length, for example, the 215 stainless-steel cannula commercially available from Valois Pharmaceuticals, Inc. Polyethylene or polypropylene cannulas can also be used.
  • compositions of the invention can also be delivered to the buccal or nasal cavity via a patch that is applied adjacent to the area of skin to be treated.
  • a “patch” comprises at least a composition of the invention and a covering layer, such that, the patch can be placed over the area to be treated.
  • the patch is designed to maximize local delivery and to minimize absorption into the circulatory system, reduce lag time, promote uniform absorption, and reduce mechanical rub-off.
  • Suitable patches are described in Transdermal and Topical Drug Delivery Systems, Interpharm Press, Inc. p. 249-297, incorporated herein by reference.
  • Suitable patches for buccal delivery of compositions of the invention is disclosed in U.S. Pat. Nos . 5,713,852 and 4,900,552, both of which are incorporated herein by reference.
  • composition of the invention applied to the buccal or nasal passages will vary depending on the particular mucoadhesive, local anesthetic, and opioid used; the nature and severity of the mucosal lesion or inflamation being treated, and the subject.
  • the composition should be applied to the affected area as recommended by a physician, preferably, as needed by the patient to relieve pain. For example, a dose of about 0.05 mg to about 4 mg morphine sulfate and 0.02 mg to about 3 mg of lidocaine hydrochloride in about 0.5g to about 3 g of composition can be delivered to the affected area.
  • a dose of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 1.5 g of composition can be delivered to the affected area.
  • a dose of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 0.4 g of composition can be delivered to the affected area.
  • the dose is delivered with a spray actuator in about 8 to about 20 separate spray shots, more preferably about 16 spray shots, wherein each spray shot weighs about 50 mg to about 150 mg, more preferably about 100 mg.
  • the dose is delivered via cannula in about 4 spray shots, wherein each spray shot weighs about 100 mg.
  • a composition of the present invention is described in Table 2 below.
  • Morphine sulfate pentahydrate (122.6 mg), lidocaine (65.4 mg) hydrochloride monohydrate, and edetate disodium dihydrate (100 mg) were dissolved in 80 g of sterile water.
  • the resulting solution was cooled to 10° C. in an ice bath and poloxmer 407 (20g) was slowly added with mixing until the Poloxmer 407 completely dissolved.
  • the solution was maintained at about 10° C. until the foam collapsed.
  • About 4 g of the solution was added to a 5 ml vial and a Valois VP7/90 18/415 pump was screwed onto the vial and refrigerated at 4° C. for 30 minutes.
  • the vial was removed from the refrigerator and the metered pump was primed using the Valois 165 actuator.
  • the Valois 165 actuator was removed and the filled vial was stored at 4° C. until the foam collapsed.
  • the vial was removed from the refrigerator and kept at room temperature (25° C.) until the contents gelled.
  • the viscosity of the above-prepared oral spray was measure using a Brookfield RVT viscometer. At 30° C. the viscosity was 82,666 cps (averaged over three determinations) and at 40° C. the viscosity was 95,666 cps (averaged over three determinations).
  • the composition can be applied as follows. Attach the long throat actuator to the metering pump and store the unit at 4° C. for at least 30 minutes. To prime the pump (7-8 sprays), with actuator in the up position, press the actuator firmly and quickly to spray into a waste container, hold the actuator for about one second when it is in the pressed position following each spray. With actuator in the up position, press the actuator firmly and quickly to spray onto the surface of the subject to be treated. Hold the actuator for two to three seconds when it is in the pressed position following each spray. Apply a total of 16 spray shots of for a total application of about 2 mg morphine sulfate and about 1 mg lidocaine hydrochloride in about 1.5 g of composition.
  • the liquid will form a viscous mucoadhesive gel. If it takes more than 90 seconds to apply 16 spray shots, store the unit at 4° C. for 10 minutes to cool the content before further usage.
  • a second composition of the present invention is described in Table 2 below.
  • Morphine sulfate pentahydrate (490.48 mg), lidocaine (261.6 mg) hydrochloride monohydrate, and edetate disodium dihydrate (100 mg ) were dissolved in 80 g of sterile water.
  • the resulting solution was cooled to 10° C. in an ice bath and poloxmer 407 (20g) was slowly added with mixing until the Poloxmer 407 completely dissolved.
  • the solution was maintained at about 10° C. until the foam collapsed.
  • About 4 g of the solution was added to a 5 ml vial and a Valois VP7/90 18/415 pump was screwed onto the vial and refrigerated at 4° C. for 30 minutes.
  • the vial was removed from the refrigerator and the metered pump was primed using the Valois 165 actuator.
  • the Valois 165 actuator was removed and the filled vial was stored at 4° C. until the foam collapsed.
  • the vial was removed from the refrigerator and kept at room temperature (25° C.) until the contents gelled.
  • the viscosity of the above-prepared oral spray was measure using a Brookfield RVT viscometer. At 30° C. the viscosity was 81,000 cps (averaged over three determinations) and at 40° C. the viscosity was 94,333 cps (averaged over three determinations).
  • composition can be applied using a long-throat actuator as described above (for spray application) or by cannula (for application to a specific area). A total of 4 spray shots is recommended.
  • the preferred actuator is a stainless-steel cannula of about 73 mm in length, for example, the 215 stainless-steel cannula commercially available from Valois Pharmaceuticals, Inc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)
US09/888,466 2000-06-26 2001-06-25 Methods and compositions for treating pain of the mucous membrane Abandoned US20020013331A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/888,466 US20020013331A1 (en) 2000-06-26 2001-06-25 Methods and compositions for treating pain of the mucous membrane
US10/172,455 US6509028B2 (en) 2000-06-26 2002-06-17 Methods and compositions for treating pain of the mucous membrane
US10/347,385 US20030124190A1 (en) 2000-06-26 2003-01-21 Methods and compositions for treating pain of the mucous membrane

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22216400P 2000-06-26 2000-06-26
US09/888,466 US20020013331A1 (en) 2000-06-26 2001-06-25 Methods and compositions for treating pain of the mucous membrane

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/172,455 Continuation US6509028B2 (en) 2000-06-26 2002-06-17 Methods and compositions for treating pain of the mucous membrane

Publications (1)

Publication Number Publication Date
US20020013331A1 true US20020013331A1 (en) 2002-01-31

Family

ID=22831130

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/888,466 Abandoned US20020013331A1 (en) 2000-06-26 2001-06-25 Methods and compositions for treating pain of the mucous membrane
US10/172,455 Expired - Lifetime US6509028B2 (en) 2000-06-26 2002-06-17 Methods and compositions for treating pain of the mucous membrane
US10/347,385 Abandoned US20030124190A1 (en) 2000-06-26 2003-01-21 Methods and compositions for treating pain of the mucous membrane

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/172,455 Expired - Lifetime US6509028B2 (en) 2000-06-26 2002-06-17 Methods and compositions for treating pain of the mucous membrane
US10/347,385 Abandoned US20030124190A1 (en) 2000-06-26 2003-01-21 Methods and compositions for treating pain of the mucous membrane

Country Status (11)

Country Link
US (3) US20020013331A1 (fr)
EP (1) EP1296650B1 (fr)
JP (2) JP2004501181A (fr)
AT (1) ATE289802T1 (fr)
AU (1) AU2001270177A1 (fr)
CA (1) CA2413545A1 (fr)
DE (1) DE60109164T2 (fr)
ES (1) ES2239144T3 (fr)
IL (2) IL153656A0 (fr)
PT (1) PT1296650E (fr)
WO (1) WO2002000195A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019022A1 (en) * 2002-07-25 2004-01-29 Karen Stec Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
US6685917B2 (en) 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
US20040208831A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
US20040209852A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Formulations and methods for treating rhinosinusitis
US20050136116A1 (en) * 2003-12-18 2005-06-23 Keith Whitehead Stabilized prednisolone sodium phosphate solutions
US20050256193A1 (en) * 2002-02-27 2005-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070128284A1 (en) * 2005-11-30 2007-06-07 Endo Pharmaceuticals Inc. Treatment of xerostomia
US20070264289A1 (en) * 2003-06-12 2007-11-15 Eot Research Inc. Compositions and methods of administering doxepin to mucosal tissue
WO2008060764A3 (fr) * 2006-10-05 2008-07-24 Drugtech Corp Traitements topiques de la mucosite orale et d'autres affections
US20080214664A1 (en) * 2007-03-02 2008-09-04 Combe Incorporated Anesthetic spray composition
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
US20090042968A1 (en) * 2004-12-23 2009-02-12 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US20090068259A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
US10722586B2 (en) 2014-11-10 2020-07-28 Universidade Federal De Pelotas Filmogenic compositions for topical anaesthetic bioadhesives—tabs, for controlled release of active principles and topical anaesthetic bioadhesives

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
AU2001281746C1 (en) 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US6602490B1 (en) * 2002-03-04 2003-08-05 Richard A. Cloonan Dental cleaning formulation and manufacturing process
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
US20050266090A1 (en) * 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
KR20060015588A (ko) * 2003-05-07 2006-02-17 디엠아이 바이오사이언시스, 인크 구강 케어 방법 및 제품
US7106483B2 (en) * 2003-06-12 2006-09-12 Ricoh Company, Limited Optical scanner and image forming apparatus
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
GB0330049D0 (en) * 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
US20070110689A1 (en) * 2004-01-15 2007-05-17 Mark Feldschuh Oral anaesthetic gel
US7947508B2 (en) * 2004-11-30 2011-05-24 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US7766658B2 (en) * 2004-11-30 2010-08-03 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US20060115785A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US20080248090A1 (en) * 2005-05-09 2008-10-09 Sunnen Gerard V Graduated concentration sodium chloride patches for the treatment of dental conditions
US20060252010A1 (en) * 2005-05-09 2006-11-09 Sunnen Gerard V Sodium chloride pad for treatment of dental conditions
EP1749528A1 (fr) 2005-08-05 2007-02-07 Pharma C S.A. Combinaisons pharmaceutiques comprenant un agoniste de l'opioide mu et un inhibiteur de la production de monoxide d'azote
US8263047B2 (en) * 2005-09-29 2012-09-11 Wickenhauser Alan J Topical anesthetic for dental procedures
US8623334B1 (en) 2005-09-29 2014-01-07 Alan J. Wickenhauser Topical anesthetic
JP5217136B2 (ja) * 2005-10-18 2013-06-19 大正製薬株式会社 直腸、尿道および膣適用用半固形状製剤。
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2645073A1 (fr) * 2006-03-08 2007-09-13 Nuviance, Inc. Composition de medicament a liberation transdermique et compositions topiques pour application cutanee
US20070231396A1 (en) * 2006-03-29 2007-10-04 Ray Charles D Medication spray formulation
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
CA2659909A1 (fr) * 2006-08-01 2008-02-07 Phrixus Pharmaceuticals, Inc. Traitement de l'insuffisance cardiaque progressive chronique
ATE440598T1 (de) * 2007-03-02 2009-09-15 Flamek Corp Ou Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden
US20080305149A1 (en) * 2007-06-11 2008-12-11 Thomas Hirt Mucoadhesive vesicles for drug delivery
KR20100056520A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 렙틴 （２２－５６）의 용도
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009064458A2 (fr) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions pour le traitement de l'inflammation des voies gastro-intestinales
MX2010006698A (es) 2007-12-17 2010-12-06 Univ Michigan Composiciones y metodos para el tratamiento y prevención de deficiencias del musculo esqueletico.
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
WO2010011605A2 (fr) 2008-07-21 2010-01-28 Otonomy, Inc. Compositions à libération contrôlée modulant la structure otique et modulant le système immunitaire naturel et procédés de traitement de troubles otiques
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
DE102008037682A1 (de) 2008-08-14 2010-04-08 Strackharn, Klaus, Dr.med. Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen
HRP20201231T1 (hr) 2008-08-20 2020-12-11 The Regents Of The University Of California Kortikosteroidi, namijenjeni liječenju upalnih bolesti gastrointestinalnog sustava
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
CA2765033C (fr) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Procedes de traitement de troubles gastro-intestinaux
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US20110117175A1 (en) * 2009-11-18 2011-05-19 Rosenbaum Richard J Sweet analgesic for use in medical procedures or treatments
WO2011066201A2 (fr) * 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Procédés et systèmes pour traiter et prévenir des lésions cardiaques chez des sujets atteints de dystrophie
US20110150955A1 (en) 2009-12-23 2011-06-23 Shannon Elizabeth Klingman Products and Methods for Reducing Malodor from the Pudendum
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
US10758619B2 (en) 2010-11-15 2020-09-01 The Ohio State University Controlled release mucoadhesive systems
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
EP3284459B1 (fr) * 2011-04-29 2021-01-06 Moberg Pharma AB Compositions pharmaceutiques comprenant un anesthésique local comme la bupivacaïne pour l'administration locale dans la bouche ou la gorge
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
FR2994844B1 (fr) * 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
AU2012397211B2 (en) 2012-12-20 2016-03-10 Colgate-Palmolive Company Oral care composition containing ionic liquids
RU2640301C2 (ru) 2013-02-07 2017-12-27 ГОНСАЛЕС Томас Бернардо ГАЛЬВАН Антисептическая композиция, предназначенная для применения в полости рта, для лечения мукозита слизистой оболочки полости рта
US20140371305A1 (en) * 2013-06-14 2014-12-18 Professional Compounding Centers Of America Mupirocin Antibiotic Composition
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
CN106659676A (zh) * 2014-11-05 2017-05-10 四川海思科制药有限公司 一种罗哌卡因缓释凝胶制剂及其制备与应用
US9943074B2 (en) * 2015-02-27 2018-04-17 Stanley James Balgaard Hinging and rotating coupler mechanism for avian spinning wing decoy
EP3328898B8 (fr) 2015-07-28 2024-04-10 6452728 Canada Corp. Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
SG11201908629WA (en) 2017-04-19 2019-10-30 Otsuka Pharma Factory Inc Anti-inflammatory agent
IL275780B2 (en) 2018-01-09 2024-07-01 Otonomy Inc Growth factor otic formulations
WO2019154895A1 (fr) 2018-02-08 2019-08-15 Strekin Ag Formulation en gel pour la prévention ou le traitement de la perte auditive
US12157869B2 (en) 2019-07-10 2024-12-03 Jeffrey Dean Lindsay Methods and compositions for reducing persistent odor in clothing and mitigating biofilms on various materials
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
US20240358716A1 (en) * 2023-04-27 2024-10-31 Citius Pharmaceuticals, Inc. Halobetasol propionate-lidocaine formulations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051234A (en) 1975-06-06 1977-09-27 The Procter & Gamble Company Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US5225196A (en) 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
DE3522550A1 (de) 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US4855142A (en) 1987-02-27 1989-08-08 Ciba-Geigy Corporation Pharmaceutical plaster
US5906810A (en) 1987-03-17 1999-05-25 Turner; Robert E. Formulations and uses thereof in the prevention and treatment of oral lesions
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5219861A (en) 1988-12-21 1993-06-15 Chugai Seiyaku Kabushiki Kaisha 6 β-Thiomorphine derivatives
US5292362A (en) 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
US5662924A (en) 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5972906A (en) 1991-07-03 1999-10-26 Hyal Pharmaceutical Corporation Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof
US5589840A (en) 1991-11-05 1996-12-31 Seiko Epson Corporation Wrist-type wireless instrument and antenna apparatus
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4223004A1 (de) 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5496811A (en) 1992-08-28 1996-03-05 Pharmos Corp. Submicron emulsions as ocular drug delivery vehicles
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5817625A (en) 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
AU6428894A (en) 1993-03-26 1994-10-24 Franciscus W.H.M. Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5578315A (en) * 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5395318A (en) 1994-01-24 1995-03-07 Kaprelian; Edward K. Method and apparatus for wound treatment
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
IT1273742B (it) 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US5635540A (en) 1994-12-09 1997-06-03 The University Of Virginia Patent Foundation Stabilized topical pharmaceutical preparations
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5713852A (en) 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
CA2230727A1 (fr) * 1995-06-16 1997-01-03 Medlogic Global Corporation Reticulats polymeriques sensibles et leurs procedes d'utilisation
JP2002516617A (ja) * 1995-06-16 2002-06-04 メドロジック グローバル コーポレイション 反応性ポリマー網状構造体及びその使用法
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
FR2742989B1 (fr) 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5667773A (en) 1996-03-12 1997-09-16 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
AU2542997A (en) * 1996-03-25 1997-10-17 Eli Lilly And Company Anesthetic method
US5747060A (en) 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
EP0829481A1 (fr) 1996-09-16 1998-03-18 Pfizer Inc. Dérivés de l'acide morphinane hydroxamique
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
ES2174337T3 (es) * 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
US5798093A (en) 1997-03-14 1998-08-25 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
US5811078A (en) 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5849762A (en) 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5989535A (en) 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment
WO1999015210A2 (fr) * 1997-09-26 1999-04-01 Noven Pharmaceuticals, Inc. Compositions bioadhesives et methodes d'administration locale d'agents actifs
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
KR100417489B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 효능제／길항제 혼합물
WO1999045906A1 (fr) * 1998-03-09 1999-09-16 Trustees Of Tufts College Traitement des comportements compulsifs chez l'homme et l'animal
EP1102589B1 (fr) 1998-07-16 2006-11-02 Memorial Sloan-Kettering Institute For Cancer Research Compositions topiques comprenant un analgesique opioide et un antagoniste du n-methyl-d-aspartate (nmda)
FR2781156B1 (fr) * 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685917B2 (en) 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
US20070071824A1 (en) * 2000-11-22 2007-03-29 Rosenthal Gary J Treatment of mucositis using N-acetylcysteine
US20070014861A1 (en) * 2000-11-22 2007-01-18 Rosenthal Gary J Treatment of proctitis
US20070014860A1 (en) * 2000-11-22 2007-01-18 Rosenthal Gary J Treatment of esophagitis
US20050256193A1 (en) * 2002-02-27 2005-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US20070224267A1 (en) * 2002-02-27 2007-09-27 Uwe Pschorn Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
WO2004010989A1 (fr) * 2002-07-25 2004-02-05 Advances Life Sciences, Inc. Utilisation des acides 2,3 alkylcarbonyloxybenzoiques, de leurs derives et analogues pour le traitement des tissus et de dysfonctionnements, alterations et lesions cellulaires chez les mammiferes
US20040019022A1 (en) * 2002-07-25 2004-01-29 Karen Stec Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals
US20050180925A1 (en) * 2003-04-16 2005-08-18 Dey, L.P. Formulations and methods for treating rhinosinusitis
US20040208830A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
US20060051299A1 (en) * 2003-04-16 2006-03-09 Merck Patent Gmbh Nasal pharmaceutical formulations and methods of using the same
US20060051300A1 (en) * 2003-04-16 2006-03-09 Merck Patent Gmbh Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US7972626B2 (en) 2003-04-16 2011-07-05 Merck Patent Gmbh Fluticasone propionate nasal pharmaceutical formulations and methods of using same
US20040209852A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US9180126B2 (en) 2003-04-16 2015-11-10 Mylan Specialty L.P. Formulations and methods for treating rhinosinusitis
US20040208831A1 (en) * 2003-04-16 2004-10-21 Imtiaz Chaudry Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20060039871A1 (en) * 2003-04-16 2006-02-23 Merck Patent Gmbh Nasal pharmaceutical formulations and methods of using the same
US7972627B2 (en) 2003-04-16 2011-07-05 Merck Patent Gmbh Beclomethasone dipropionate monohydrate nasal pharmaceutical formulations and methods of using the same
US20080050442A1 (en) * 2003-04-16 2008-02-28 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20080058295A1 (en) * 2003-04-16 2008-03-06 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20080058296A1 (en) * 2003-04-16 2008-03-06 Imtiaz Chaudry Formulations and methods for treating rhinosinusitis
US8663695B2 (en) 2003-04-16 2014-03-04 Mylan Specialty L.P. Formulations and methods for treating rhinosinusitis
US8309061B2 (en) 2003-04-16 2012-11-13 Dey Pharma, L.P. Formulations and methods for treating rhinosinusitis
US8158154B2 (en) 2003-04-16 2012-04-17 Dey Pharma, L.P. Nasal pharmaceutical formulations and methods of using the same
US8129364B2 (en) 2003-04-16 2012-03-06 Dey Pharma, L.P. Formulations and methods for treating rhinosinusitis
US20070264289A1 (en) * 2003-06-12 2007-11-15 Eot Research Inc. Compositions and methods of administering doxepin to mucosal tissue
US20050136116A1 (en) * 2003-12-18 2005-06-23 Keith Whitehead Stabilized prednisolone sodium phosphate solutions
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US20090035385A1 (en) * 2004-12-22 2009-02-05 Drugtech Corporation Compositions including iron
US20090028962A1 (en) * 2004-12-22 2009-01-29 Drugtech Corporation Methods and Compositions for Enhancing Iron Absorption
US20110015150A1 (en) * 2004-12-22 2011-01-20 Drugtech Corporation Methods of administering compositions including iron
US20090042968A1 (en) * 2004-12-23 2009-02-12 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US10258693B2 (en) 2005-07-22 2019-04-16 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070020187A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US8574552B2 (en) 2005-07-22 2013-11-05 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US7501452B2 (en) 2005-11-30 2009-03-10 Endo Pharmaceuticals Inc. Treatment of xerostomia
US20070128284A1 (en) * 2005-11-30 2007-06-07 Endo Pharmaceuticals Inc. Treatment of xerostomia
WO2008060764A3 (fr) * 2006-10-05 2008-07-24 Drugtech Corp Traitements topiques de la mucosite orale et d'autres affections
US20100240749A9 (en) * 2007-03-02 2010-09-23 Combe Incorporated Anesthetic spray composition
US20080214664A1 (en) * 2007-03-02 2008-09-04 Combe Incorporated Anesthetic spray composition
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090068259A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa
US10512597B2 (en) * 2007-09-06 2019-12-24 Colgate-Palmolive Company Controlled surface gelling of mucoadhesive polymers on oral mucosa
US20110091618A1 (en) * 2009-10-16 2011-04-21 Frito-Lay North America, Inc. Method for preventing oxidation and off flavors in high carotenoid foods
US10722586B2 (en) 2014-11-10 2020-07-28 Universidade Federal De Pelotas Filmogenic compositions for topical anaesthetic bioadhesives—tabs, for controlled release of active principles and topical anaesthetic bioadhesives

Also Published As

Publication number Publication date
IL153656A (en) 2010-05-31
WO2002000195A2 (fr) 2002-01-03
PT1296650E (pt) 2005-06-30
US6509028B2 (en) 2003-01-21
US20030124190A1 (en) 2003-07-03
JP2009001574A (ja) 2009-01-08
DE60109164D1 (de) 2005-04-07
ATE289802T1 (de) 2005-03-15
DE60109164T2 (de) 2005-12-29
IL153656A0 (en) 2003-07-06
EP1296650A2 (fr) 2003-04-02
JP2004501181A (ja) 2004-01-15
ES2239144T3 (es) 2005-09-16
EP1296650B1 (fr) 2005-03-02
WO2002000195A3 (fr) 2002-08-15
CA2413545A1 (fr) 2002-01-03
AU2001270177A1 (en) 2002-01-08
US20020192288A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
US6509028B2 (en) Methods and compositions for treating pain of the mucous membrane
US9814705B2 (en) Intranasal spray device containing pharmaceutical composition
US8846641B2 (en) Stabilized ophthalmic galactomannan formulations
CA2356881A1 (fr) Compositions ameliorees d'apport de principes actifs
HU199678B (en) Process for producing aerosols containing nitroglicerol
US20080221144A1 (en) Controlled Release Formulations
JP7359909B2 (ja) 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。
EP1559418A1 (fr) Compositions pour le traitement analgesique de la muqueuse
HK1076258A (en) Compositions for treating pain of the mucous membrane
US7332528B2 (en) DRI nasal sprays
JP7133981B2 (ja) 外用組成物
JP2015509933A (ja) 安定性が強化された水性医薬組成物
JP7125862B2 (ja) 外用組成物
JP5238779B2 (ja) 点鼻剤

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION